AbbVie announced that it has submitted applications for a new indication to the U.S. FDA and European Medicines Agency for upadacitinib for the treatment of adult patients with giant cell arteritis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: